August 18, 2014

From July 29 to Aug. 18, people have donated $15.6 million to the ALS Association as the result of the viral Ice Bucket Challenge. 


August 15, 2014

The Food and Drug Administration announced approval of a new use for Avastin (bevacizumab), to treat patients with persistent, recurrent or late-stage cervical cancer.

August 15, 2014

Mallinckrodt announced that it has completed the acquisiton of Questcor Pharmaceuticals in a transaction valued at $5.8 billion.

August 14, 2014

The National Association of Specialty Pharmacy on Thursday announced that Bob Fulcher has joined the organization as COO. 

August 14, 2014

Beginning in August, Wegmans Food Markets is now offering an enhanced Specialty Pharmacy Service for medications used to treat conditions in the fields of rheumatology, gastroenterology, neurology and dermatology.

August 8, 2014

Diplomat on Thursday announced that its president, Gary Kadlec, has been elected to the board of directors for the American Foundation of Pharmaceutical Education. 

August 4, 2014

The Food and Drug Administration approved Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are younger than 8 years of age.

July 31, 2014

McKesson on Thursday reported revenues of $44.1 billion for the first quarter ended June 30, up 37%. 

July 28, 2014

The Food and Drug Administration on Monday expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia who carry a deletion in chromosome 17.

July 25, 2014

The National Association of Specialty Pharmacy  and the Specialty Pharmacy Association of America announced the merger of the two organizations, creating the largest professional and trade association focused on the unique needs in specialty pharmacy. 

July 24, 2014

Onco360, an independent oncology pharmacy and clinical support services company, announced that it has been selected to be part of the highly limited specialty pharmacy network of Zydelig tablets.

July 23, 2014

The Food and Drug Administration on Wednesday announced approval for Zydelig (idelalisib) to treat patients with chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma.

July 21, 2014

AbbVie has finalized a deal for Dublin-based specialty pharmaceuticals company Shire for $54.7 billion.

July 21, 2014

Illinois Gov. Pat Quinn signed a bill Monday that opens up medical marijuana to treat symptoms of epilepsy in adults and children.

July 21, 2014

Commentary published online Monday addresses the controversy surrounding the high costs of new Hepatitis C virus treatments and implications for the growing specialty pharmacy market. 


July 18, 2014

The Food and Drug Administration on Thursday announced the approval of Ruconest, a recombinant C1-Esterase inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.

July 17, 2014

Diplomat announced it has acquired MedPro Rx, a specialty pharmacy focused on specialty infusion therapies including hemophilia and immune globulin.


July 16, 2014

Sun Life Assurance Company of Canada entered into a strategic business relationship with McKesson Canada to launch the Sun Life Preferred Pharmacy Network.

July 14, 2014

 Diplomat on Saturday hosted a ‘Keep Kids Safe and Healthy’ event at the specialty pharmacy's retail store.

July 14, 2014

Shire announced that the company requested and has received a revised proposal from AbbVie that would value a proposed merger deal at $53 billion.

July 14, 2014

Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business.

July 14, 2014

Although the pace of approvals for new orphan drugs — medicines that treat relatively rare conditions — have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs, a newly completed study released last week by the Tufts Center for the Study of Drug Development at Tufts University has concluded.

July 7, 2014

Novo Nordisk on Monday announced that the Food and Drug Administration approved the company's NovoSeven RT (coagulation factor VIIa [recombinant]).

July 3, 2014

Diplomat Pharmacy on Thursday announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock.